US equities
|
MU
$953.19
▼-3.62%
NVDA
$228.52
▲+0.97%
META
$762.50
▲+2.63%
AAPL
$341.27
▲+0.09%
MSFT
$543.45
▲+0.43%
SNDK
$1,482.33
▼-0.34%
AMD
$605.53
▲+1.90%
SPCX
$156.54
▼-4.21%
MU
$953.19
▼-3.62%
NVDA
$228.52
▲+0.97%
META
$762.50
▲+2.63%
AAPL
$341.27
▲+0.09%
MSFT
$543.45
▲+0.43%
SNDK
$1,482.33
▼-0.34%
AMD
$605.53
▲+1.90%
SPCX
$156.54
▼-4.21%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Biovaxys Technology Corp
(OP:
BVAXF
)
0.0900
UNCHANGED
Delayed Quote
Updated: 9:30 AM EDT, Oct 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Biovaxys Technology Corp
< Previous
1
2
Next >
BioVaxys Presents Further Validation of the Robust Immune Response from a Combination of MVP-S with Checkpoint Inhibitors and Low-Dose Cyclophosphamide in Ovarian Cancer
May 01, 2026
Unique MRI Study Shows How the Combination Exerts its Effect
Via
TheNewswire.com
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
April 28, 2026
VANCOUVER, BC, April 28 2026 - TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB0) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) is providing this bi-weekly update on the status of the...
Via
TheNewswire.com
BioVaxys Announces Phase I/II PESCO Trial Abstract Accepted for Presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2026
VANCOUVER, BC, April 27th, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV OTCQB:BVAXF FRA:5LB0) today announced the acceptance of an abstract related to the PESCO study, an...
Via
TheNewswire.com
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
April 13, 2026
VANCOUVER, BC, March 17, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) is providing this bi-weekly update on the status of the...
Via
TheNewswire.com
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
March 31, 2026
VANCOUVER, BC, March 31, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB0) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) is providing this bi-weekly update on the status of the...
Via
TheNewswire.com
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
March 17, 2026
VANCOUVER, BC, March 17, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) is providing this bi-weekly update on the status of the...
Via
TheNewswire.com
BioVaxys and AI-Guided mRNA Immunotherapy Leader Adiverna Enter Collaboration to Develop Companion Animals Vaccines
March 10, 2026
Via
TheNewswire.com
Topics
Artificial Intelligence
BioVaxys Announces Application for Management Cease Trade Order
March 03, 2026
Vancouver, BC – TheNewswire - March 3rd, 2026 – BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) announces that it was unable to file its annual financial...
Via
TheNewswire.com
BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer
January 29, 2026
Reinforces Synergistic Potential and Expands Opportunity Beyond Ovarian Cancer
Via
TheNewswire.com
BioVaxys 1Q2026 R&D and Collaborative Activity
January 15, 2026
Via
TheNewswire.com
2025 Corporate Review
December 31, 2025
Via
TheNewswire.com
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer
December 17, 2025
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or...
Via
Newsfile
BioVaxys Strengthens Scientific Team with Addition of Former IMV Vice President of R&D
December 15, 2025
Via
TheNewswire.com
Topics
Intellectual Property
InvestorNewsBreaks – BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (FRA: 5LB), SpayVac-for-Wildlife Inc. Expand License Agreement
April 22, 2025
Via
Investor Brand Network
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
September 20, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
BioVaxys Technology Corp. to Present at the Life Sciences Investor Forum September 19th 2024
September 17, 2024
BioVaxys invites individual and institutional investors, as well as advisors and analysts, to attend online at www.VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
September 16, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
December 01, 2022
EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Intellectual Property
BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine
December 01, 2022
Vancouver, BC – December 1, 2022 – BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or “Company”) is pleased to announce the successful sterile and bacteria-free test-run...
Via
FinancialNewsMedia
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
October 06, 2022
Palm Beach, FL – October 6, 2022 – FinancialNewsMedia.com News Commentary – The global Cervical Cancer Treatment market has been expanding for several years and is projected to continue at a growing...
Via
FinancialNewsMedia
BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps
October 06, 2022
Agreement Includes Right of First Refusal in the US for Ovosicare and Libicare Vancourver, BC – October 6, 2022 – BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or...
Via
FinancialNewsMedia
Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression
May 18, 2022
Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – Companies in the Ovarian Cancer market are spending a lot of R&D on vaccine development, therapies and studies. For the past 30...
Via
FinancialNewsMedia
Topics
Death
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement
May 18, 2022
Vancouver, BC – May 18, 2022 — BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or “Company”), announced today that Hospices Civils de Lyon, France (“HCL”) has agreed to...
Via
FinancialNewsMedia
Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating
April 25, 2022
Palm Beach, FL – April 25, 2022 – FinancialNewsMedia.com News Commentary – The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer...
Via
FinancialNewsMedia
Topics
Intellectual Property
BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction
April 25, 2022
Vancouver, BC – April 25, 2022 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys” or “Company”), announced today that it has entered into an agreement with the Deaconess Research...
Via
FinancialNewsMedia
Topics
Economy
Race to Develop Universal ‘Variant-Proof’ Covid Vaccine Involves Several Players
March 24, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2022 – USA News Group – Whenever a new COVID-19 variant emergences, health authorities have had limited options to fight...
Via
FinancialNewsMedia
Biotech Sector’s Response to Omicron Panic Should be Swift and Effective
December 07, 2021
FN Media Group Presents USA News Group News Commentary Vancouver, BC – December 7, 2021 – USA News Group – Despite a level of panic that JP Morgan has already downplayed in its 2022 forecasts, the...
Via
FinancialNewsMedia
Anxious World Waits As Covid Vaccine Makers Address Omicron Variant
December 07, 2021
Palm Beach, FL – December 7, 2021 – FinancialNewsMedia.com News Commentary There are many unknowns surrounding the new omicron Covid variant; there are early signs it’s more transmissible, but it’s not...
Via
FinancialNewsMedia
BIOVAXYS ANNOUNCES MAJOR RESEARCH COLLABORATION WITH THE OHIO STATE UNIVERSITY TO DEVELOP BROADLY REACTIVE PAN-SARBECOVIRUS VACCINE
December 07, 2021
VANCOUVER, BC – December 7, 2021 – BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV.CNQ) (OTCQB:BVAXF) (“BioVaxys” or “Company”), a clinical-stage immunotherapy company developing novel approaches...
Via
FinancialNewsMedia
Covid-19 Test Shortage Emphasized by New $70M Plan to Speed Up Authorizations
November 09, 2021
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 9, 2021 – USA News Group – New at-home Covid tests are on the way, according to the Biden administration, which announced...
Via
FinancialNewsMedia
< Previous
1
2
Next >
